Targeting human EGFR 2 (HER2) in salivary gland carcinoma
Sign Up to like & getrecommendations! Published in 2023 at "Expert Review of Anticancer Therapy"
DOI: 10.1080/14737140.2023.2208350
Abstract: ABSTRACT Introduction Human epidermal growth factor receptor 2 (HER2) protein overexpression, gene amplification, and activating mutations have been identified in a subset of salivary gland carcinoma (SGC) histologies (HER2-positive), especially in salivary duct carcinoma, and… read more here.
Keywords: her2; gland carcinoma; trastuzumab; salivary gland ... See more keywords
The Therapeutic Effectiveness of Neoadjuvant Trastuzumab Plus Chemotherapy for HER2-Positive Breast Cancer Can Be Predicted by Tumor-Infiltrating Lymphocytes and PD-L1 Expression
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2021.706606
Abstract: Introduction Neoadjuvant trastuzumab plus chemotherapy may affect programmed death-ligand 1 (PD-L1) expression and tumor-infiltrating lymphocytes (TILs) in HER2-positive breast cancer. Discordant results were shown on the correlation between PD-L1 expression or TILs and the effectiveness… read more here.
Keywords: breast cancer; plus chemotherapy; cancer; trastuzumab plus ... See more keywords
Mode of action of pertuzumab in combination with trastuzumab plus docetaxel therapy in a HER2-positive breast cancer xenograft model
Sign Up to like & getrecommendations! Published in 2017 at "Oncology Letters"
DOI: 10.3892/ol.2017.6679
Abstract: In a Phase III trial for HER2-positive breast cancer (the CLEOPATRA study), the triple-drug combination arm of pertuzumab plus trastuzumab plus docetaxel showed significantly longer progression-free survival and overall survival than did the trastuzumab plus… read more here.
Keywords: combination; triple drug; trastuzumab plus; plus docetaxel ... See more keywords